The Lancet: AI-supported mammography screening results in fewer aggressive and advanced breast cancers, finds full results from first randomized controlled trial
Peer-Reviewed Publication
Updates every hour. Last Updated: 21-Jun-2026 15:15 ET (21-Jun-2026 19:15 GMT/UTC)
National Institutes of Health (NIH)-supported investigators have developed a blood test to find pancreatic ductal adenocarcinoma, one of the deadliest forms of cancer. The new test could improve survival rates from pancreatic cancer, which tends to be diagnosed at late stages when therapy is less likely to be effective. The findings were published in Clinical Cancer Research.
The lower hinge of immunoglobulin G (IgG), an overlooked part of the antibody, acts as a structural and functional control hub, according to a study by researchers at Science Tokyo. Deleting a single amino acid in this region transforms a full-length antibody into a stable half-IgG1 molecule with altered immune activity. The findings provide a blueprint for engineering next-generation antibody therapies with precisely tailored immune effects for treating diseases such as cancer and autoimmune diseases.
Researchers at NYU Abu Dhabi have developed a new light-based nanotechnology that could improve how certain cancers are detected and treated, offering a more precise and potentially less harmful alternative to chemotherapy, radiation, and surgery.
Unrepaired DNA-protein crosslinks (DPCs) – highly toxic tangles of protein and DNA – cause a process that leads to premature aging and embryonic lethality in mice. The findings reveal a previously unrecognized link between defective DNA repair and immune-driven inflammatory disease. They also suggest that targeting innate immune signaling may offer a therapeutic strategy for human disorders like Ruijs-Aalfs progeria syndrome (RJALS), which are caused by defective DPC repair. DPCs form when proteins become covalently trapped to DNA. These harmful knots block essential cellular processes, including DNA replication and transcription. The protease SPRTN plays a critical role in maintaining genome stability by repairing DPCs during DNA replication. While its role during DNA replication is well established, its functions in other phases of the cell cycle are less understood. Moreover, inherited mutations in SPRTN are known to cause RJALS – a rare disorder marked by premature aging and early-onset liver cancer.
Through cellular analyses, Ines Tomaskovic and colleagues show that SPRTN repairs DPCs not only during DNA replication, but also during mitosis. Loss of SPRTN causes DPC accumulation, leading to chromosome segregation defects and the formation of micronuclei containing persistent DPCs and damaged DNA. DNA released from aberrant nuclei accumulates in the cytoplasm and is detected by the cGAS-STING innate immune pathway, triggering inflammatory signaling. To assess the physiological impact of this response, Tomaskovic et al. generated a mouse model carrying the RJALS-associated SPRTN mutation. The authors found that these animals accumulated unrepaired DPCs and micronuclei, showed a strong innate immune response, and exhibited key features of the human disorder, including reduced body size, craniofacial and eye abnormalities, and premature hair graying, with some defects arising during embryogenesis. Notably, inhibition of cGAS-STING from early development rescued mice from developmental lethality and premature aging caused by DPC accumulation.
An enduring challenge for the study of human cancer is just how complex it is: how many different ways there are for cancers to originate, progress, and spread in the people who are diagnosed with them. In a review publishing January 29 in the Cell Press journal Cell, biologist Douglas Hanahan of the Ludwig Institute for Cancer Research in Lausanne, Switzerland, offers a major update to his long-standing framework to help those studying cancer make sense of its remarkable diversity and complexity.